Artiva Biotherapeutics Inc
ARTV2.880USD
+0.500+21.01%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
70.25MMarket Cap
LossP/E TTM
More Details of Artiva Biotherapeutics Inc Company
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. The Company's product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as LN, RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, SLE and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Company Info
Ticker SymbolARTV
Company nameArtiva Biotherapeutics Inc
IPO dateJul 19, 2024
CEODr. Fred Aslan, M.D.
Number of employees89
Security typeOrdinary Share
Fiscal year-endJul 19
Address5505 Morehouse Drive
CitySAN DIEGO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code92121
Phone18582674467
Websitehttps://www.artivabio.com/
Ticker SymbolARTV
IPO dateJul 19, 2024
CEODr. Fred Aslan, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
40.97K
-3.85%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
2.41K
-35.76%
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Dr. Alison Moore, Ph.D.
Dr. Alison Moore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher P. Horan
Mr. Christopher P. Horan
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Dr. Brian Daniels, M.D.
Dr. Brian Daniels, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
40.97K
-3.85%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
2.41K
-35.76%
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q1
FY2022
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
40.34%
GC Biopharma Corp
18.70%
5AM Ventures
9.63%
VR Adviser, LLC
6.59%
VenBio Partners LLC
4.70%
Other
20.03%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
40.34%
GC Biopharma Corp
18.70%
5AM Ventures
9.63%
VR Adviser, LLC
6.59%
VenBio Partners LLC
4.70%
Other
20.03%
Shareholder Types
Shareholders
Proportion
Venture Capital
57.76%
Corporation
18.70%
Private Equity
4.70%
Investment Advisor/Hedge Fund
4.51%
Hedge Fund
4.08%
Investment Advisor
4.06%
Individual Investor
1.15%
Research Firm
0.82%
Other
4.21%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
104
25.61M
104.85%
+2.90M
2025Q1
101
26.68M
109.52%
+4.03M
2024Q4
89
26.90M
110.75%
+5.25M
2024Q3
74
26.42M
108.79%
+10.37M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
9.85M
40.44%
--
--
Mar 31, 2025
GC Biopharma Corp
4.57M
18.75%
+4.57M
--
Jul 22, 2024
5AM Ventures
2.35M
9.66%
--
--
Mar 31, 2025
VR Adviser, LLC
1.61M
6.61%
--
--
Mar 31, 2025
VenBio Partners LLC
1.20M
4.92%
-321.00K
-21.12%
Mar 31, 2025
Franklin Advisers, Inc.
520.33K
2.14%
+26.00
+0.00%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.16M
4.74%
+189.32K
+19.60%
Mar 31, 2025
Samsara BioCapital, LLC
291.67K
1.2%
--
--
Mar 31, 2025
Woodline Partners LP
283.12K
1.16%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
